Q-omics provides the consensus-scored SHISA6 profile across patient tissues and cancer cell-line models. SHISA6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SHISA6 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, SHISA6 RNA expression shows 13,953 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KICH, and TGCT as cancer lineages where SHISA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SHISA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SHISA6 survival associations across molecular data types. SHISA6 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SHISA6 RNA expression–survival associations across cancer types. High SHISA6 expression shows unfavorable associations in DLBC, UVM and BLCA, but favorable associations in UCEC, KIRC and UCS. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SHISA6 RNA expression.
This table summarizes SHISA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SHISA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SHISA6 shows lower tumor expression in KICH, KIRC, KIRP, BLCA and STAD and higher tumor expression in THCA. The KICH box plot shows higher SHISA6 RNA expression in normal versus tumor tissue (log2 FC = −1.790, t-test p < 0.001).
This table shows molecular features associated with SHISA6 in patient tissues and cancer cell lines. In patient samples, SHISA6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SHISA6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
